Immunosuppressive activities of adenosine in cancer

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Tumors employ immunosuppressive mechanisms to evade immune detection.
• Extracellular adenosine accumulation, mediated by purinergic receptors, is a key tumor escape strategy.
• Adenosine signaling via A2a and A2b receptors normally regulates immune responses but is hijacked in cancer.

Purpose of the Study:

• To review the immunosuppressive effects of extracellular adenosine in cancer.
• To discuss the therapeutic potential of adenosine pathway inhibitors.
• To highlight ongoing clinical trials targeting adenosine-mediated immunosuppression.

Main Methods:

• Literature review of recent studies on adenosine and anti-tumor immunity.
• Analysis of therapeutic strategies targeting CD73 and adenosine receptors.
• Discussion of current clinical trial data for adenosine inhibitors.

Main Results:

• Extracellular adenosine potently suppresses anti-tumor immunity.
• CD73 is a critical enzyme in adenosine production within the tumor microenvironment.
• Inhibition of CD73 or adenosine receptors shows therapeutic promise.

Conclusions:

• Targeting the adenosine pathway represents a promising strategy to enhance anti-tumor immunity.
• Clinical trials investigating anti-CD73 antibodies and A2a receptor antagonists are underway.
• Development of adenosine inhibitors is crucial for overcoming tumor-induced immunosuppression.